On May 5, 2025, BioSig Technologies, Inc. (NASDAQ: BSGM), a medical technology company, announced it had signed a Letter of Intent to merge with Streamex Exchange Corporation, a real-world asset tokenization company focused on commodities. The proposed all-stock transaction was designed to bring Streamex public on the Nasdaq. Terms outlined that Streamex shareholders would initially receive 19.9% of BioSig’s common stock, along with Series X Convertible Preferred Stock, which upon shareholder approval would raise their total stake to 75%, leaving BioSig shareholders with 25%.

Streamex operates decentralized exchange and primary issuance infrastructure for on-chain commodities markets using blockchain and Solana technology. Leadership changes were also announced, with Streamex co-founder Henry McPhie to become CEO and Morgan Lekstrom to serve as Chairman, while BioSig CEO Anthony Amato would transition to the board.

On May 28, 2025, the companies confirmed the successful closing of the share exchange transaction. Streamex became a wholly owned subsidiary of BioSig, and the leadership changes took effect. The combined company positions itself in the $142 trillion global commodities market, aiming to modernize commodity finance through tokenization. Strategic advisors include Frank Giustra, Mathew August, and Mitchell Williams, bringing extensive experience in commodities, capital markets, and finance.

This merger marks the transformation of BioSig into a publicly traded tokenization company focused on bridging traditional commodities with blockchain-based markets.